SLU-PP-332 Compound Reference
Published · Last updated · Publisher: ENOS Labs USA
What is SLU-PP-332?
SLU-PP-332 is a synthetic small molecule, not a peptide, that activates the estrogen related receptors ERRalpha, beta and gamma. Mouse studies published from 2023 examined it as an exercise mimetic in muscle metabolism and metabolic syndrome models. It has no human trial data and is not an approved drug.
- Synonyms
- ERR agonist SLU-PP-332
- Classification
- Synthetic small molecule agonist of estrogen related receptors (not a peptide)
What is SLU-PP-332?
SLU-PP-332 was developed at Saint Louis University as a pan ERR agonist.
Research context
Research covers endurance capacity and muscle fiber metabolism in mice, obesity and metabolic syndrome models, heart failure models, and anti doping analytical characterization.
Mechanisms being investigated
- Agonism at ERRalpha, beta and gamma, nuclear receptors that regulate mitochondrial and fatty acid metabolism genes.
Research status
Approval status: Not approved for human use. Highest evidence tier in the cited literature: preclinical.
Preclinical. Not approved for any use, and anti doping laboratories have flagged it as a compound with doping potential.
Established findings
- ERR agonist activity in cell assays.
Preliminary or experimental findings
- All metabolic and exercise findings, which come from mice.
Chemical reference information
| Molecular formula | C18H14N2O2 |
|---|---|
| Molecular weight | 290.3 g/mol |
| CAS number | 303760-60-3 |
| PubChem CID | 5338394 |
Values taken from the PubChem record.
Testing considerations
- Small molecule: identity by MS and NMR, purity by HPLC; solubility in aqueous media is limited.
General methods are explained in purity versus identity testing.
What is still unknown
- Pharmacology and safety in humans.
Related resources
ENOS catalog listing: SLU-PP-332 10MG
Research use limitations
This page summarizes published research and regulatory status. It is not medical advice and does not describe any use in people. Material supplied by ENOS Labs USA is for in-vitro laboratory research only and is not a drug product, even where a related drug has been approved.
To continue, see mitochondrial peptide research, how to read a certificate of analysis, why purity and identity are separate tests, the compound directory and the peptide testing glossary.
References
Each source below was opened and checked against its PubMed, ClinicalTrials.gov or PubChem record. Links open in a new tab.
- Synthetic ERRalpha/beta/gamma Agonist Induces an ERRalpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity (PMID 36988910)ACS Chemical Biology, 2023 · PubMed
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome (PMID 37739806)The Journal of Pharmacology and Experimental Therapeutics, 2024 · PubMed
- In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential (PMID 41588687)Rapid Communications in Mass Spectrometry, 2026 · PubMed
- SLU-PP-332 compound record (PubChem CID 5338394)PubChem · NIH National Library of Medicine
These products are sold strictly for in-vitro laboratory research and are not intended for human consumption, diagnosis, treatment, or any therapeutic use. Purchaser must be 18 years of age or older and confirms they are a qualified researcher.